Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cystadenocarcinoma, Serous"" wg kryterium: Temat


Wyświetlanie 1-19 z 19
Tytuł:
Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
Autorzy:
Choi J; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Topouza DG; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Tarnouskaya A; School of Computing, Queen's University, Kingston, Ontario, Canada.
Nesdoly S; School of Computing, Queen's University, Kingston, Ontario, Canada.
Koti M; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Duan QL; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. .; School of Computing, Queen's University, Kingston, Ontario, Canada. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 May 13; Vol. 20 (1), pp. 413. Date of Electronic Publication: 2020 May 13.
Typ publikacji:
Journal Article
MeSH Terms:
Gene Regulatory Networks*
Quantitative Trait Loci*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*genetics
Chemotherapy, Adjuvant/*methods
Cystadenocarcinoma, Serous/*pathology
Ovarian Neoplasms/*pathology
Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/genetics ; Drug Resistance, Neoplasm ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Neoplasm Grading ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics
Czasopismo naukowe
Tytuł:
ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Autorzy:
Nadaraja S; Department of Oncology, Odense University Hospital, Odense, Denmark.; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.
Schledermann D; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.; Department of Pathology, Odense University Hospital, Odense, Denmark.
Herrstedt J; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.; Department of Clinical Oncology, Zealand University Hospital, Roskilde, Denmark.
Østrup O; Center for Genomic Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
Ditzel HJ; Department of Oncology, Odense University Hospital, Odense, Denmark.; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Pokaż więcej
Corporate Authors:
Academy of Geriatric Cancer Research (AgeCare)
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Jan; Vol. 59 (1), pp. 40-47. Date of Electronic Publication: 2019 Sep 03.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carrier Proteins/*metabolism
Cystadenocarcinoma, Serous/*drug therapy
Cystadenocarcinoma, Serous/*metabolism
GTPase-Activating Proteins/*metabolism
Ovarian Neoplasms/*drug therapy
Ovarian Neoplasms/*metabolism
Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carrier Proteins/genetics ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/pathology ; Female ; GTPase-Activating Proteins/genetics ; Gene Expression Profiling ; Humans ; Neoplasm Grading ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Retrospective Studies ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Autorzy:
Wu C; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, China.; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang City, China.
He L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, China.; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang City, China.
Wei Q; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, China.; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang City, China.
Li Q; Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang City, China.
Jiang L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, China.; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang City, China.
Zhao L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, China.; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang City, China.
Wang C; Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang City, China.
Li J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, China.; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang City, China.; Liaoning Blood Center, Liaoning Provincial Key Laboratory for Blood Safety Research, Shenyang, China.
Wei M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang City, China.; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang City, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Feb; Vol. 9 (3), pp. 1242-1253. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Biomarkers, Tumor/*genetics
Cystadenocarcinoma, Serous/*drug therapy
Drug Resistance, Neoplasm/*genetics
Organoplatinum Compounds/*pharmacology
Ovarian Neoplasms/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Computational Biology ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/mortality ; Cystadenocarcinoma, Serous/pathology ; Datasets as Topic ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Models, Genetic ; Oligonucleotide Array Sequence Analysis/statistics & numerical data ; Organoplatinum Compounds/therapeutic use ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Phosphatidylinositol 3-Kinases/metabolism ; Prognosis ; Progression-Free Survival ; RNA, Messenger ; ROC Curve ; Transcriptome/genetics
Czasopismo naukowe
Tytuł:
Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Autorzy:
Bandolik JJ; Institute for Pharmaceutical and Medicinal Chemistry, University of Duesseldorf, 40225 Duesseldorf, Germany. .
Hamacher A; Institute for Pharmaceutical and Medicinal Chemistry, University of Duesseldorf, 40225 Duesseldorf, Germany. .
Schrenk C; Institute for Pharmaceutical and Medicinal Chemistry, University of Duesseldorf, 40225 Duesseldorf, Germany. .
Weishaupt R; Institute for Computer Science, Computational Complexity and Cryptology, University of Duesseldorf, 40225 Duesseldorf, Germany. .
Kassack MU; Institute for Pharmaceutical and Medicinal Chemistry, University of Duesseldorf, 40225 Duesseldorf, Germany. .
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2019 Jun 22; Vol. 20 (12). Date of Electronic Publication: 2019 Jun 22.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cisplatin/*therapeutic use
Cystadenocarcinoma, Serous/*drug therapy
Histone Deacetylase Inhibitors/*pharmacology
Ovarian Neoplasms/*drug therapy
Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis ; Benzamides/pharmacology ; Benzamides/therapeutic use ; Cell Line, Tumor ; Cell Survival ; Cystadenocarcinoma, Serous/enzymology ; Cystadenocarcinoma, Serous/physiopathology ; Drug Synergism ; Female ; Histone Deacetylase Inhibitors/therapeutic use ; Histone Deacetylases ; Humans ; Hydroxamic Acids/pharmacology ; Hydroxamic Acids/therapeutic use ; Ovarian Neoplasms/enzymology ; Ovarian Neoplasms/physiopathology ; Panobinostat/pharmacology ; Panobinostat/therapeutic use ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Pyridines/pharmacology ; Pyridines/therapeutic use
Czasopismo naukowe
Tytuł:
Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin.
Autorzy:
Zhang J; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
Xie S; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
Zhou L; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
Tang X; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
Guan X; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Deng M; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
Zheng H; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
Wang Y; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
Lu R; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. .
Guo L; Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No.270, Dong'An Road, Xuhui District, Shanghai, 200032, China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2021 Sep 17; Vol. 14 (1), pp. 122. Date of Electronic Publication: 2021 Sep 17.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Carcinoma, Ovarian Epithelial/*drug therapy
Carcinoma, Ovarian Epithelial/*metabolism
Cystadenocarcinoma, Serous/*drug therapy
Cystadenocarcinoma, Serous/*metabolism
Glutathione Transferase/*metabolism
Carboplatin/administration & dosage ; Carcinoma, Ovarian Epithelial/pathology ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Female ; Humans ; Middle Aged ; Paclitaxel/administration & dosage ; Up-Regulation
Czasopismo naukowe
Tytuł:
Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer.
Autorzy:
He Y; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, China.
Li T; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, China.
Liu J; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, China.
Ou Q; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, China.
Zhou J; Clinical Research Institute, The First Affiliated Hospital of University of South China, Hengyang, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Feb 12; Vol. 20 (1), pp. 116. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Cystadenocarcinoma, Serous/*complications
Neutropenia/*etiology
Ovarian Neoplasms/*complications
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cystadenocarcinoma, Serous/drug therapy ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/drug therapy ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review.
Autorzy:
Yuan J; Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
He L; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing, 100038, People's Republic of China.
Han B; Department of Pathology, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA.
Li Y; Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing, 100038, People's Republic of China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2017 Apr 11; Vol. 15 (1), pp. 76. Date of Electronic Publication: 2017 Apr 11.
Typ publikacji:
Case Reports; Journal Article; Review
MeSH Terms:
Cytoreduction Surgical Procedures*
Hyperthermia, Induced*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cystadenocarcinoma, Papillary/*mortality
Cystadenocarcinoma, Serous/*mortality
Peritoneal Neoplasms/*mortality
Carboplatin/administration & dosage ; Chemotherapy, Cancer, Regional Perfusion ; Combined Modality Therapy ; Cystadenocarcinoma, Papillary/pathology ; Cystadenocarcinoma, Papillary/therapy ; Cystadenocarcinoma, Serous/pathology ; Cystadenocarcinoma, Serous/therapy ; Docetaxel ; Female ; Humans ; Middle Aged ; Neoplasm Grading ; Peritoneal Neoplasms/pathology ; Peritoneal Neoplasms/therapy ; Prognosis ; Survival Rate ; Taxoids/administration & dosage ; Thoracic Surgery, Video-Assisted
Czasopismo naukowe
Tytuł:
Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Autorzy:
Gao H; Department of Gynaecology, The Third Affiliated Hospital of Harbin Medical University, 150# Hapin Street, Xiangfang District, Harbin, 150040, Heilongjiang, China.
Yuan L; Social Medicine Department of Harbin Medical University, 157# Baojian Road, Nan'gang District, Harbin, 150081, Heilongjiang, China.
Han Y; Department of Gynaecology, The Third Affiliated Hospital of Harbin Medical University, 150# Hapin Street, Xiangfang District, Harbin, 150040, Heilongjiang, China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2016 Jun 24; Vol. 14 (1), pp. 168. Date of Electronic Publication: 2016 Jun 24.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Papillary/*mortality
Cystadenocarcinoma, Serous/*mortality
Ovarian Neoplasms/*mortality
Adult ; Aged ; Aged, 80 and over ; Carboplatin/administration & dosage ; Carcinoma, Papillary/drug therapy ; Carcinoma, Papillary/pathology ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Postoperative Care ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł:
High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
Autorzy:
Miyamoto M; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Takano M; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Iwaya K; Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Shinomiya N; Department of Molecular Biology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Goto T; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Kato M; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Suzuki A; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Aoyama T; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Hirata J; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Nagaoka I; Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan.
Tsuda H; Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Furuya K; Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Feb 17; Vol. 112 (4), pp. 739-44. Date of Electronic Publication: 2015 Jan 27.
Typ publikacji:
Journal Article
MeSH Terms:
Biomarkers, Tumor*/metabolism
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cystadenocarcinoma, Serous/*diagnosis
Cystadenocarcinoma, Serous/*drug therapy
Mitochondrial Proteins/*physiology
Ovarian Neoplasms/*diagnosis
Ovarian Neoplasms/*drug therapy
Serine Endopeptidases/*physiology
Adult ; Aged ; Aged, 80 and over ; Cell Line, Tumor ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Disease-Free Survival ; Female ; High-Temperature Requirement A Serine Peptidase 2 ; Humans ; Middle Aged ; Neoplasm Grading ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Prognosis ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Autorzy:
Li Y; Department of Gynaecology and Obstetrics, Tianjin Hospital, Tianjin 300211, China.
Yang Y
Shang YM
Zheng H
Pokaż więcej
Źródło:
Indian journal of cancer [Indian J Cancer] 2014 Mar; Vol. 51 Suppl 3, pp. e92-4.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma, Papillary/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Transitional Cell/*drug therapy
Cystadenocarcinoma, Serous/*drug therapy
Drug Resistance, Neoplasm/*drug effects
Neoplasm Recurrence, Local/*drug therapy
Ovarian Neoplasms/*drug therapy
Adenocarcinoma, Papillary/mortality ; Adenocarcinoma, Papillary/pathology ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Bevacizumab ; Carcinoma, Transitional Cell/mortality ; Carcinoma, Transitional Cell/pathology ; Cystadenocarcinoma, Serous/mortality ; Cystadenocarcinoma, Serous/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Epirubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Ifosfamide/administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Prognosis ; Retrospective Studies ; Survival Rate ; Gemcitabine
Czasopismo naukowe
Tytuł:
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Autorzy:
Lesnock JL; Magee-Women's Hospital of UPMC, Division of Gynecologic Oncology, Pittsburgh PA 15213, USA.
Darcy KM
Tian C
Deloia JA
Thrall MM
Zahn C
Armstrong DK
Birrer MJ
Krivak TC
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Apr 02; Vol. 108 (6), pp. 1231-7. Date of Electronic Publication: 2013 Mar 05.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma, Clear Cell/*mortality
Adenocarcinoma, Mucinous/*mortality
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
BRCA1 Protein/*metabolism
Cystadenocarcinoma, Serous/*mortality
Endometrial Neoplasms/*mortality
Ovarian Neoplasms/*mortality
Adenocarcinoma, Clear Cell/drug therapy ; Adenocarcinoma, Clear Cell/metabolism ; Adenocarcinoma, Mucinous/drug therapy ; Adenocarcinoma, Mucinous/metabolism ; Adult ; Aged ; Aged, 80 and over ; Cisplatin/administration & dosage ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/metabolism ; Endometrial Neoplasms/drug therapy ; Endometrial Neoplasms/metabolism ; Female ; Follow-Up Studies ; Humans ; Immunoenzyme Techniques ; Injections, Intraperitoneal ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/metabolism ; Paclitaxel/administration & dosage ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł:
A case of primary retroperitoneal serous adenocarcinoma.
Autorzy:
Arichi N; Department of Urology, Shimane University School of Medicine, Izumo, Shimane, Japan. />Yasumoto H
Mitsui Y
Hiraoka T
Honda S
Shiina H
Igawa M
Pokaż więcej
Źródło:
International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2011 Dec; Vol. 18 (12), pp. 844-6. Date of Electronic Publication: 2011 Oct 12.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cystadenocarcinoma, Serous/*drug therapy
Cystadenocarcinoma, Serous/*surgery
Retroperitoneal Neoplasms/*drug therapy
Retroperitoneal Neoplasms/*surgery
Aged ; Carboplatin/administration & dosage ; Chemotherapy, Adjuvant ; Cystadenocarcinoma, Serous/pathology ; Docetaxel ; Female ; Humans ; Retroperitoneal Neoplasms/pathology ; Taxoids/administration & dosage
Czasopismo naukowe
Tytuł:
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Autorzy:
Sharma R; Department of Experimental Medicine, Imperial College, London, UK. />Graham J
Blagden S
Gabra H
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2011 Jul 11; Vol. 11, pp. 289. Date of Electronic Publication: 2011 Jul 11.
Typ publikacji:
Case Reports; Clinical Trial; Journal Article
MeSH Terms:
Salvage Therapy*
Adenocarcinoma/*drug therapy
Antineoplastic Agents, Phytogenic/*pharmacology
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Blood Platelets/*drug effects
Carboplatin/*pharmacology
Ovarian Neoplasms/*drug therapy
Paclitaxel/*pharmacology
Thrombocytopenia/*prevention & control
Adenocarcinoma/blood ; Adenocarcinoma/surgery ; Adenocarcinoma, Papillary/blood ; Adenocarcinoma, Papillary/drug therapy ; Adenocarcinoma, Papillary/surgery ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Agents, Phytogenic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Area Under Curve ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Cisplatin/administration & dosage ; Combined Modality Therapy ; Cystadenocarcinoma, Serous/blood ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/surgery ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Etoposide/administration & dosage ; Female ; Granulosa Cell Tumor/blood ; Granulosa Cell Tumor/drug therapy ; Granulosa Cell Tumor/surgery ; Humans ; Middle Aged ; Ovarian Neoplasms/blood ; Ovarian Neoplasms/surgery ; Ovariectomy ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Peripheral Nervous System Diseases/chemically induced ; Tamoxifen/administration & dosage ; Thrombocytopenia/chemically induced ; Treatment Outcome
Czasopismo naukowe
Tytuł:
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
Autorzy:
Fruscio R; Clinica Ostetrica e Ginecologica, University of Milan-Bicocca, San Gerardo Hospital, Monza, Italy. />Colombo N
Lissoni AA
Garbi A
Fossati R
Ieda' N
Torri V
Mangioni C
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2008 Feb 26; Vol. 98 (4), pp. 720-7. Date of Electronic Publication: 2008 Feb 05.
Typ publikacji:
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasms, Glandular and Epithelial/*drug therapy
Ovarian Neoplasms/*drug therapy
Adenocarcinoma, Clear Cell/diagnosis ; Adenocarcinoma, Clear Cell/drug therapy ; Adenocarcinoma, Clear Cell/mortality ; Adenocarcinoma, Mucinous/diagnosis ; Adenocarcinoma, Mucinous/drug therapy ; Adenocarcinoma, Mucinous/mortality ; Adult ; Aged ; Carcinoma, Endometrioid/diagnosis ; Carcinoma, Endometrioid/drug therapy ; Carcinoma, Endometrioid/mortality ; Cisplatin/administration & dosage ; Cystadenocarcinoma, Serous/diagnosis ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/mortality ; Epirubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Ifosfamide/administration & dosage ; Middle Aged ; Neoplasms, Glandular and Epithelial/diagnosis ; Neoplasms, Glandular and Epithelial/mortality ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/mortality ; Paclitaxel/administration & dosage ; Survival Rate ; Time Factors
Czasopismo naukowe
Tytuł:
Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.
Autorzy:
Ray-Coquard I; Centre Léon Bérard, EA 4129 sis, 28 rue Laënnec, Lyon 69008, France. />Paraiso D
Guastalla JP
Leduc B
Guichard F
Martin C
Chauvenet L
Haddad-Guichard Z
Lepillé D
Orfeuvre H
Gautier H
Castera D
Pujade-Lauraine E
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2007 Nov 05; Vol. 97 (9), pp. 1200-5. Date of Electronic Publication: 2007 Oct 09.
Typ publikacji:
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Ovarian Neoplasms/*drug therapy
Adolescent ; Adult ; Aged ; Carboplatin/administration & dosage ; Carcinoma, Endometrioid/drug therapy ; Cisplatin/administration & dosage ; Cyclophosphamide/administration & dosage ; Cystadenocarcinoma, Serous/drug therapy ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.
Autorzy:
Hasan J; Cancer Research UK, Department Medical Oncology, Christie Hospital, Wilmslow Road, Withington, Manchester M20 4BX, UK. />Ton N
Mullamitha S
Clamp A
McNeilly A
Marshall E
Jayson GC
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2005 Sep 19; Vol. 93 (6), pp. 647-51.
Typ publikacji:
Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cystadenocarcinoma, Serous/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Neoplasms, Glandular and Epithelial/*drug therapy
Ovarian Neoplasms/*drug therapy
Aged ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Goserelin/administration & dosage ; Humans ; Maximum Tolerated Dose ; Middle Aged ; Salvage Therapy ; Survival Rate ; Tamoxifen/administration & dosage
Czasopismo naukowe
    Wyświetlanie 1-19 z 19

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies